AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) A <u>druggedl death inhibitor</u> comprising, as an active ingredient, an indolylmaleimide derivative represented by the following formula (I):

(II)

wherein R¹ represents an <u>unsubstituted</u> alkyl group, <u>unsubstituted alkenyl</u>, <u>which may be substituted</u>, an aryl group which may be substituted, an aryl group which may be substituted, hydroxyl group, an alkoxyl group which may be substituted, an aryloxy group which may be substituted, an aryloxy group which may be substituted, an adverse a hydrogen atom, an <u>unsubstituted</u> alkyl-group, <u>unsubstituted alkenyl or unsubstituted alkynyl</u> which may be substituted, an alkenyl group which may be substituted, an alkynyl group which may be substituted, an aryl group which may be substituted, an alkoxy or aryloxycarbonyl group which may be substituted, an alkyl- or arylthiocarbonyl group which may be substituted, an alkyl- or

substituted, an alkyl-or arylsulfonyl group which may be substituted, an alkoxyl group which may be substituted, an aryloxy group which may be substituted, or hydroxyl group; R3 represents substituent(s) on an indole ring, and represents, number and position (2-, 4-, 5-, 6-, or 7-position as position number of the indole ring) of the substituent(s) and kinds of the substituent(s) may be the same or different, hydrogen, unsubstituted alkyl, unsubstituted alkenyl, or unsubstituted alkynyl-atom, an alkyl-group which may be substituted, an alkenyl-group which may be substituted, an alkynyl group which may be substituted, an aryl group which may be substituted. an acyl group which may be substituted, an alkoxy-or aryloxycarbonyl group which may be substituted, an alkoxy- or aryloxycarbonyloxy group which may be substituted, an alkyl- or arylthiocarbonyl group which may be substituted, an aminocarbonyl group which may be substituted, an alkyl-or arylsulfonyl group which may be substituted, an alkoxyl group which may be substituted, an aryloxy group which may be substituted, an alkyl- or arylthic group which may be substituted, hydroxyl group, carboxyl group, evano group, nitro group, an amino group which may be substituted, or a halogen atom; R4 represents hydrogen atom, an alkyl group which may be substituted, an alkenyl group which may be substituted, an alkynyl group which may be substituted, an aryl group which may be substituted (except 3 indolyl group), an acyl group which may be substituted, an alkoxy- or aryloxycarbonyl group which may be substituted, an alkyl- or arylthiocarbonyl group which may be substituted, an aminocarbonyl group which may be substituted, an alkyl- or arylsulfonyl group which may be substituted, an alkoxyl group which may be substituted, an aryloxy group which may be substituted, alkyl- or arylthic group which may be substituted, hydroxyl group, earboxyl group, eyene group, nitro group, or amino

group which may be substituted; R² and R³, R² and R⁴, R³ and R⁴ may be combined to form a hydrocarbon chain which may be substituted; and in the formula, the bond accompanying a dotted line represents a double bond or a single bond, or a pharmaceutically acceptable salt thereof.

- 2. (currently amended) A drug for treating or preventing progress of symptoms, through inhibiting death of neurons associated with, of neurodegenerative diseases such as Alzheimer's disease, spinal muscular artophy (SMA), amyotrophic lateral screrosis (ALS), Parkinson's disease, Huntington's disease, pigmentary degeneration of the retina, glaucoma and cerebellar degeneration, comprising a indolylmaleimide derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
- 3. (currently amended) A drug for treating or preventing progress of symptoms, through inhibiting death of neurons associated with of neonatal jaundice, comprising a indolylmaleimide derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
- 4. (currently amended) A drug for treating or preventing-progress of symptoms, through inhibiting cell death associated with, of myasthenia gravis, comprising a indolylmaleimide derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.

4

- 5. (currently amended) A drug for treating or preventing progress of symptoms, through inhibiting death of neurons associated with, of brain ischemia and delayed neuronal death (DND), comprising a indolylmaleimide derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
- 6. (currently amended) A drug for treating or preventing-progress of symptoms, through inhibiting death of myocardial cells associated with, of ischemic heart disease, viral myocarditis, autoimmune myocarditis, myocardial disorders/cell death due to hypertrophic heart and heart failure, or arrythmogenic right ventricular cardiomyopathy, comprising a indolylmaleimide derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
- 7. (currently amended) A drug for treating or preventing progress of symptoms, through inhibiting death of hepatic cells associated with of alcoholic hepatitis or viral hepatitis, comprising a indolylmaleimide derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
- (currently amended) A drug for treating or preventing-progress of symptoms, through inhibiting death of renal cells associated with, of renal diseases, comprising a indolylmaleimide

Amendment under 37 C.F.R. § 1,111 USSN 10/069,007

derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.

- 9. (currently amended) A drug for treating or preventing-progress of symptoms, through inhibiting excessive death of T-cells associated with, of acquired immunodeficiency syndrome (AIDS), comprising a indolylmaleimide derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
- 10. (currently amended) A drug for treating or preventing progress of symptoms, through inhibiting cell death associated with, of inflammatory skin disorders, alopecia, or graft versus host disease (GVH), comprising a indolylmaleimide derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
- 11. (currently amended) A drug for treating or preventing disorders or side effects, through inhibiting cell death associated with, of disorders due to radiation or drugs, comprising a indolylmaleimide derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
- 12. (currently amended) A drug for treating or preventing progress of symptoms, through inhibiting cell death associated with, of sepsis, comprising a indolylmaleimide derivative

Amendment under 37 C.F.R. § 1.111 USSN 10/069,007

represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.

- 13. (currently amended) A drug for treating or preventing progress of symptoms, through inhibiting death of cells derived from bone marrow, wherein said cell death is associated without osteomyelo-dysplasia, comprising a indolylmaleimide derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
- 14. (currently amended) A drug for treating or preventing progress of symptoms, through inhibiting cell death associated with, of insulin dependent diabetes, comprising a indolylmaleimide derivative represented by the above formula [H] or a pharmaceutically acceptable salt thereof as an active ingredient.
- 15. (currently amended) A drug for treating or preventing progress of symptoms, through inhibiting death of neurons associated with, of prion diseases, comprising a indolylmaleimide derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
- 16. (currently amended) A drug for treating or preventing <u>cell death associated with</u> functional deficiency of transplanted organs, tissues or cells at transplantation of organs, tissues

Amendment under 37 C.F.R. § 1.111 USSN 10/069,007

or cells, comprising a indolylmaleimide derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.

17. (original) A preservative for organs, tissues or cells, comprising a indolylmaleimide derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.